1. Home
  2. TGHL vs CURX Comparison

TGHL vs CURX Comparison

Compare TGHL & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.31

Market Cap

10.5M

Sector

Technology

ML Signal

N/A

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$0.49

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGHL
CURX
Founded
2020
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
11.6M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
TGHL
CURX
Price
$0.31
$0.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.1K
404.5K
Earning Date
05-18-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.26
52 Week High
$3.80
$9.18

Technical Indicators

Market Signals
Indicator
TGHL
CURX
Relative Strength Index (RSI) 39.74 59.09
Support Level $0.29 $0.37
Resistance Level $0.51 $0.51
Average True Range (ATR) 0.03 0.05
MACD -0.00 0.00
Stochastic Oscillator 10.81 55.68

Price Performance

Historical Comparison
TGHL
CURX

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Share on Social Networks: